EUVIMEDEUVIMED entdecken
Fallbericht

D-Penicillamine Induced Myelotoxicity: A Unique Case

Aliya Abdulla iD, Aryan Rezvani, Christopher Nelsen, Mariah I Sigala

Journal of Pharmacy Practice · 2025-08 · 38 (4) · 414-418

DOI: 10.1177/08971900241308626 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 11.12.2024. Verfasst von Aliya Abdulla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Houston Methodist Hospital, Houston, TX, USA. Hauptthemen laut MEDLINE: Penicillamine, Pancytopenia, Chelating Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A case of D-penicillamine-related myelotoxicity in a patient with Wilson’s disease is reported. Summary: There is a paucity of literature regarding D-penicillamine (DPA) induced myelotoxicity in the setting of Wilson’s disease (WD). A 22-year-old male presented with a 1-week history of bleeding gums and dizziness. Four months prior, he had been diagnosed with Wilson’s disease and started on a regimen of DPA. His blood counts demonstrated profound pancytopenia. Due to concern for suspected drug-induced myelotoxicity, DPA was discontinued. Parvovirus B19, Epstein-Barr virus, cytomegalovirus, and varicella zoster virus polymerase chain reaction studies were negative and there was no evidence of hematological malignancy. Bone marrow biopsy demonstrated hypocellularity and trilineage hypoplasia with corresponding aspirate flow cytometry confirming the absence of acute leukemia. The patient was started on subcutaneous granulocyte-colony stimulating factor, provided transfusion support with packed red blood cells and platelets. Despite these measures, his blood count failed to recover, and he was discharged on eltrombopag 150 mg daily with plans for outpatient transfusion support. DPA was permanently discontinued, and he was prescribed trientine 750 mg daily. Unfortunately, his myelotoxicity remained consistent, requiring regular transfusions. He is currently undergoing evaluation for bone marrow transplant.

Conclusion

DPA-induced myelotoxicity is a rare clinical entity. Our case demonstrates a unique clinical presentation of this phenomenon. Guidelines to mitigate the risk of and treat this toxicity remain to be determined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PenicillaminePancytopeniaChelating AgentsHumansMaleYoung AdultBone Marrow

Stichwörter der Autor:innen

D-penicillamineWilson’s diseasechelatormyelotoxicitypancytopenia

Substanzen

PenicillamineChelating Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Houston Methodist Hospital, Houston, TX, USA.
  • School of Medicine, Texas A&M Health Science Center, Bryan, TX, USA.

ORCID-Profile: Aliya Abdulla

Zitieren

APA

Abdulla, A., Rezvani, A., Nelsen, C., & Sigala, M. I. (2025). D-Penicillamine Induced Myelotoxicity: A Unique Case. Journal of Pharmacy Practice, 38(4), 414-418. https://doi.org/10.1177/08971900241308626

Vancouver

Abdulla A, Rezvani A, Nelsen C, Sigala MI. D-Penicillamine Induced Myelotoxicity: A Unique Case. Journal of Pharmacy Practice. 2025;38(4):414-418. doi:10.1177/08971900241308626

BibTeX
@article{Abdulla2025,
  author = {Abdulla, Aliya and Rezvani, Aryan and Nelsen, Christopher and Sigala, Mariah I},
  title = {D-Penicillamine Induced Myelotoxicity: A Unique Case},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  volume = {38},
  number = {4},
  pages = {414--418},
  doi = {10.1177/08971900241308626}
}
Kostenlos starten →